Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil

A. V. Bedini, L. Tavecchio, C. Lequaglie, G. Ravasi

Research output: Contribution to journalArticle

Abstract

Background: One regimen consisting of a continuous infusion of cisplatin and fluorouracil was designed to be minimally toxic, and suitable for application with radiotherapy in non-small-cell lung carcinoma (NSCLC). Patients and methods: Forty-four NSCLC patients received daily 8 mg/m2 of cisplatin on days 1-2, 8-9, 15-16, 22-23, and 300 mg/m2 of fluorouracil on days 3-7, 10-14, 17-21, 24-28 (35-day courses). Results: Two patients experienced grade 3-4 toxicities. Eleven achieved objective responses. The median progression-free and observed survival was 22 and 39.5 weeks. Conclusions: The schedule management was fully ambulatory. Toxicity was negligible. The activity was moderate, but the combination with radiotherapy is advisable due to the radioenhancing properties of both of the drugs.

Original languageEnglish
Pages (from-to)838-840
Number of pages3
JournalAnnals of Oncology
Volume6
Issue number8
Publication statusPublished - 1995

Keywords

  • cisplatin
  • continuous infusion
  • fluorouracil
  • lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Hematology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology

Fingerprint Dive into the research topics of 'Ambulatory low-toxicity chemotherapy in non-small-cell lung carcinoma by continuous 28-day infusion of alternating cisplatin and 5-fluorouracil'. Together they form a unique fingerprint.

  • Cite this